首页> 外文OA文献 >Combination Therapy of Capecitabine with Cyclophosphamide as a Second-Line Treatment after Failure of Paclitaxel Plus Bevacizumab Treatment in a Human Triple Negative Breast Cancer Xenograft Model

【2h】

Combination Therapy of Capecitabine with Cyclophosphamide as a Second-Line Treatment after Failure of Paclitaxel Plus Bevacizumab Treatment in a Human Triple Negative Breast Cancer Xenograft Model

机译：在人类三阴性乳腺癌异种移植模型中，紫杉醇加贝伐单抗治疗失败后，卡培他滨联合环磷酰胺作为二线治疗。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Mieko Yanagisawa; Keigo Yorozu; Mitsue Kurasawa; Yoichiro Moriya; Naoki Harada;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 奥沙利铂和卡培他滨联合贝伐单抗加放疗的新辅助方案治疗局部晚期直肠癌:单中心Ⅱ期研究结果 [J] . Xin Yu, De-sen Wan, Pei-rong Ding, 癌症（英文版） . 2018,第008期
2. Combination Therapy of Capecitabine with Cyclophosphamide as a Second-Line Treatment after Failure of Paclitaxel plus Bevacizumab Treatment in a Human Triple Negative Breast Cancer Xenograft Model [J] . Mieko Yanagisawa, Keigo Yorozu, Mitsue Kurasawa, Journal of Cancer Therapy . 2013,第7期

机译：在人类三阴性乳腺癌异种移植模型中，紫杉醇加贝伐单抗治疗失败后，卡培他滨联合环磷酰胺作为二线治疗。
3. Weekly Paclitaxel, Capecitabine, and Bevacizumab With Maintenance Capecitabine and Bevacizumab as First-Line Therapy for Triple-Negative, Metastatic, or Locally Advanced Breast Cancer: Results From the GINECO A-TaXel Phase 2 Study [J] . Ferrero Jean-Marc, Hardy-Bessard Anne-Claire, Capitain Olivier, Cancer: A Journal of the American Cancer Society . 2016,第20期

机译：每周紫杉醇，卡培他滨和贝伐单抗联合维持用卡培他滨和贝伐单抗作为三阴性，转移性或局部晚期乳腺癌的一线治疗：GINECO A-TaXel 2期研究的结果
4. A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2- negative primary breast cancer [J] . MasudaN., HigakiK., TakanoT., Cancer chemotherapy and pharmacology. . 2014,第2期

机译：紫杉醇/环磷酰胺/卡培他滨节律性紫杉醇联合5-氟尿嘧啶/厄比霉素/环磷酰胺作为三阴性或低激素受体表达/ HER2-阴性原发性乳腺癌的术前化疗的II期研究
5. Acoustic Cluster Therapy displays theranostic capability in enhancing the effectiveness of liposomal doxorubicin treatment of human triple negative breast cancer in mice [C] . Nigel Bush, Andrew Healey, Anant Shah, IEEE International Ultrasonics Symposium . 2019

机译：声学聚类疗法在提高小鼠中提高人类三重阴性乳腺癌的脂质体Doxorubicin治疗的有效性方面的治疗能力
6. Effects of EGCG and DAC Combinational Treatment on Treating Triple Negative Breast Cancer and Aiding Immune Checkpoint Blockage Therapies [D] . Wang, Zixu. 2019

机译：EGCG和DAC组合治疗对治疗三重阴性乳腺癌的影响及辅助免疫检查点梗阻疗法
7. Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter phase II single arm trial (GIM11-BERGI) [O] . C. De Angelis, D. Bruzzese, A. Bernardo, 2021

机译：Eribulin与Bevacizumab相结合作为HER2阴性转移性乳腺癌的二线治疗在与紫杉醇和Bevacizumab的一线治疗后进展：多中心II期单臂试验（GIM11-BERGI）
8. Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’ [O] . C. De Angelis, D. Bruzzese, A. Bernardo, 2021

机译：勘探为“二林蛋白与Bevacizumab相结合，作为HER2阴性转移性乳腺癌的二线治疗，与紫杉醇和Bevacizumab具有一线治疗后进展：多中心，II期，单臂试验（GIM11-Bergi）'

Combination Therapy of Capecitabine with Cyclophosphamide as a Second-Line Treatment after Failure of Paclitaxel Plus Bevacizumab Treatment in a Human Triple Negative Breast Cancer Xenograft Model

著录项

相似文献

相关主题

期刊订阅